This study aims to characterize the spectrum of fusion partners and resistance mutations in patients with ROS1+ NSCLC and to analyze treatment responses to different lines of TKI therapy using real‐world data and the Ba/F3 preclinical cell line model. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.